Advertisement
Advertisement
DNA
Ginkgo Bioworks Holdings, Inc.
12.01
USDSponsored
-0.36
-2.91%
Nov 10, 15:59 UTC -5
Closed
After-Market
12.01
0.00
-0.02%
Ginkgo Bioworks Holdings, Inc. (DNA) Earnings
DNA Earnings Reports
Positive Surprise Ratio
DNA beat 9 of 21 last estimates.
43%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Ginkgo Bioworks Holdings, Inc. earnings per share and revenue
On Nov 05, 2026, DNA reported earnings of -0.64 USD per share (EPS) for Q3 26, beating the estimate of -0.87 USD, resulting in a 27.17% surprise. Revenue reached 27.71 million, compared to an expected 21.78 million, with a 27.22% difference. The market reacted with a +13.35% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kura Oncology, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.83
Actual
-$0.78
Surprise
+7.00%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Autolus Therapeutics plc - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-27.20%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
Seer, Inc. Class A Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.25
Actual
-$0.25
Surprise
+1.96%
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
TELA Bio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.13
Surprise
+20.54%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
FAQ
What were Ginkgo Bioworks Holdings, Inc.'s earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Ginkgo Bioworks Holdings, Inc. reported EPS of -$0.64, beating estimates by 27.17%, and revenue of $27.71M, 27.22% above expectations.
How did the market react to Ginkgo Bioworks Holdings, Inc.'s Q3 2026 earnings?
The stock price moved up 13.35%, changed from $9.96 before the earnings release to $11.29 the day after.
When is Ginkgo Bioworks Holdings, Inc. expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Ginkgo Bioworks Holdings, Inc.'s next earnings report?
Based on --
analysts, Ginkgo Bioworks Holdings, Inc. is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.